Growth & GH-AxisListed — currently OOS

CJC-1295 (No DAC)

GHRH analog (short-acting modified GHRH(1-29), aka Mod GRF 1-29)

A short-acting form of CJC-1295 lacking the Drug Affinity Complex, referenced in pulsatile GH-release research.

Also referenced as: CJC-1295 NS, Mod GRF 1-29

29 aat½ Short, on the order of tens of minutes (reported approximately 30 minutes), longer than native GHRH but far shorter than the DAC version

Overview

CJC-1295 without DAC (commonly called Mod GRF 1-29 or Modified GRF 1-29) is a modified GHRH(1-29) analog carrying stabilizing amino-acid substitutions but lacking the albumin-binding Drug Affinity Complex (DAC) of the full CJC-1295.

At a glance

ClassGHRH analog (short-acting modified GHRH(1-29), aka Mod GRF 1-29)

CategoryGrowth & GH-Axis

SequenceTyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2

Chain length29 amino acids

Molecular weightApproximately 3368 g/mol

Half-lifeShort, on the order of tens of minutes (reported approximately 30 minutes), longer than native GHRH but far shorter than the DAC version

Typical formLyophilized powder

AliasesCJC-1295 NS, Mod GRF 1-29

Use designationResearch / in-vitro only

Regulatory statusCJC-1295 without DAC (Mod GRF 1-29) is not approved by the FDA or EMA for any indication; it is used in research contexts only and is not an approved medicine.

What CJC-1295 (No DAC) does

CJC-1295 without DAC — often called Modified GRF 1-29 (Mod GRF 1-29) — is the GHRH-analog backbone carrying the four stabilizing amino acid substitutions but LACKING the Drug Affinity Complex. Those substitutions make it resistant to DPP-4 breakdown, so it lasts longer than plain sermorelin, but without the albumin-binding DAC its half-life is still short (roughly 30 minutes to a couple of hours). Functionally this is the defining feature: it acts as a brief, potent GHRH trigger that produces a sharp, discrete GH pulse and then clears, closely mimicking the body's natural episodic pattern of GH secretion.

Because it drives amplitude of a GH pulse rather than sustaining a continuous plateau, no-DAC CJC-1295 is the form typically paired with a ghrelin-mimetic GHS-R agonist (ipamorelin, GHRP-2, or GHRP-6). The GHRH analog and the ghrelin mimetic hit complementary pathways — one increases the GH released per pulse while the other primes the pituitary and suppresses somatostatin — so their combination generates a larger synergistic burst than either alone. The trade-off versus the DAC version is dosing frequency: the short action requires more frequent administration but yields a more physiologic, pulsatile profile that is subject to normal feedback.

Evidence is primarily mechanistic and early-pharmacology; it is a research compound, not an approved drug, and human outcome trials are lacking.

Effects reported in research

Triggered a sharp, short-lived GH pulse via GHRH-receptor agonism, mimicking natural episodic secretion (mechanistic/PK basis).
Resisted DPP-4 degradation through four amino acid substitutions, outlasting native GHRH/sermorelin.
Cleared quickly (short half-life without DAC), preserving pulsatility and normal feedback rather than a sustained plateau.
Amplified GH pulse amplitude — raising GH released per pulse rather than pulse frequency.
Synergized strongly with ghrelin-mimetic secretagogues (ipamorelin/GHRP-2/GHRP-6) for a larger combined GH burst (preclinical/combination studies).
Raised downstream IGF-1 in proportion to the GH pulses generated.
Remains research-use only; no large human efficacy trials for body composition or performance.

Effects listed reflect findings reported in the research literature — many in animal or in-vitro models. Listing an effect is not a claim of efficacy or a therapeutic indication in humans.

Mechanism of action

This peptide is a GHRH-receptor agonist that stimulates pulsatile GH release from the pituitary. Its four amino-acid substitutions on the GHRH(1-29) backbone (e.g. at positions 2, 8, 15, 27) resist DPP-4 degradation, giving it a modestly longer half-life than native sermorelin. Without the DAC group, it does not bind albumin, so it produces short, discrete GH pulses rather than sustained elevation.

Mechanistic description reflects published research-literature understanding. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.

What it's studied for

Research contexts in which CJC-1295 (No DAC) appears in the literature. Listing a research area is not a claim of efficacy or a therapeutic indication.

Key characteristics

Modified GHRH(1-29) with DPP-4-resistant substitutions but no DAC
Short-acting (minutes) versus the multi-day half-life of CJC-1295 with DAC
Produces discrete GH pulses rather than a sustained 'bleed'
Often studied paired with ipamorelin or GHRP-2 for additive GH release
Longer-acting than native sermorelin due to its stabilizing substitutions

Reported research dosing reference only

Educational reference, not dosing guidance. The figures below summarize amounts reported in published research and research-community protocols, provided for educational and research context only. They are not medical advice, not a recommendation, and not instructions for human use. CJC-1295 (No DAC) is a research compound.

CJC-1295 no-DAC is referenced in the research literature at roughly 100 mcg (about 1-2 mcg/kg) per administration, reflecting its short half-life. These are reference figures for research context only, not dosing guidance for humans.

Common research-protocol reference: ~100 mcg per subcutaneous dose
Body-weight-scaled reference: ~1-2 mcg/kg per dose

Reported frequencyReported 1-3 times daily in research protocols, reflecting the ~30 minute half-life

ReconstitutionLyophilized; typically reconstituted with bacteriostatic water for research use

Short-acting (no albumin binding); ~30 min half-life for pulsatile GH modeling. Reference figures only, not human dosing guidance.

How it compares

The absence of the DAC albumin-binding group makes this a short-acting, pulse-generating GHRH analog, in direct contrast to the long-acting DAC version of CJC-1295.

Commonly studied alongside

Compounds frequently researched together with CJC-1295 (No DAC) in the literature. Cross-referenced for research context — not a usage or combination recommendation.

IpamorelinShort-acting GHRH analog + selective GHRP is the classic pulsatile-GH research pairing.GHRP-2Co-studied to combine short-acting GHRH-receptor and ghrelin-receptor stimulation.GHRP-6Ghrelin-receptor GHRP paired with the short-acting GHRH analog for synergistic GH pulses.

Compare and calculate

Side-by-side pages for the pairings the literature already documents for CJC-1295 (No DAC), plus the unit-conversion reference for a reconstituted vial. Factual comparisons of documented characteristics — not a recommendation to combine or use any compound.

Handling & Stability

Lyophilized peptides are stored cold, protected from light, and reconstituted only at the time of intended in-vitro work.

Avoid repeated freeze-thaw cycles
Verify supplier lot and Certificate of Analysis
Follow institutional lab-safety protocols

Analytical & COA Concepts

Reputable research suppliers publish a third-party Certificate of Analysis per batch. Key analytical concepts referenced in COAs include:

Category Context

CJC-1295 (No DAC) sits in the Growth & GH-Axis area of the PeptiDex library.

Research Supplier Listing

Where researchers source CJC-1295 (No DAC)

For researchers studying CJC-1295 (No DAC), third-party suppliers such as Practically Natty Peptides offer research-grade material, third-party tests every batch and provides Certificates of Analysis on request, and ship from the US. This specific listing is currently marked out of stock — check the supplier site for current availability.

View research-supplier listing →

Outbound link to a third-party research supplier. Inclusion does not constitute endorsement; all editorial content is developed independently.

Frequently asked questions

What is CJC-1295 without DAC?

CJC-1295 without DAC (essentially Modified GRF 1-29) is a synthetic 29-amino-acid GHRH analog with four substitutions (at positions 2, 8, 15, and 27) that resist DPP-IV cleavage. Unlike the DAC version, it lacks the albumin-binding complex, so it is short-acting.

How does the no-DAC version differ from CJC-1295 with DAC?

Both share the same modified GHRH(1-29) core, but the no-DAC form has a half-life of only about 30 minutes and produces discrete GH pulses, whereas the DAC form binds albumin and lasts 6-8 days, giving sustained GHRH tone. The choice shapes whether research models pulsatile or sustained GH output.

Is CJC-1295 no-DAC the same as Modified GRF (1-29)?

Effectively yes. CJC-1295 without DAC and Modified GRF (1-29) refer to the same tetra-substituted GHRH(1-29) peptide; the naming differs by supplier but the sequence and short-acting profile are the same.

Why is the no-DAC form preferred for pulsatile GH research?

Its short (~30 minute) half-life mimics the body's natural pulsatile GHRH signaling. Paired with a short-acting GHRP like ipamorelin, it produces a clean, discrete GH pulse, which is why it is favored in research modeling physiologic GH release.

Is CJC-1295 no-DAC an approved drug?

No. It is not an approved medication and is available only as a research chemical, not for human therapeutic use.

Answers are educational summaries of research-literature context and do not constitute medical advice. See the Research Library, COA guide, and Storage & Handling guide for more.

References

Primary literature indexed in PubMed for CJC-1295 (No DAC). Listing a study records that it exists and is indexed — it is not a claim of efficacy, a therapeutic indication, or an endorsement of its conclusions. Much of this literature is preclinical (in-vitro or animal-model).

Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog Endocrinology, 2005. PubMed 15817669
Catabolism of rat growth hormone-releasing factor(1-29) amide in rat serum and liver Peptides, 1992. PubMed 1437711

Each reference was checked against its PubMed record on 2026-07-28: the PMID resolves and the title, journal and year match. Where no indexed literature exists for a compound, PeptiDex says so rather than substituting a citation about a different molecule. See the editorial policy.